BIIB


Biogen Spikes 10% On FDA Fast Review For Potential Alzheimer Treatment 

Shares in Biogen leaped 10% on Friday after the company said that the U.S.

Biogen, Eisai Start New Phase 3 Trial For Pre-clinical Alzheimer’s Disease

Biogen (BIIB), in collaboration with Eisai, and the Alzheimer’s Clinical Trials Consortium, has initiated a new global Phase 3 clinical study (AHEAD 3-45) …

Biogen Files FDA Application For Potential Alzheimer Treatment 

Biogen Inc. (BIIB) announced that it has finally submitted the Biologics License Application (BLA) seeking approval by the Food and Drug Administration (FDA) …

Biogen Announces 1Q20 Beat, But Aducanumab Update Steals The Show

Biogen (BIIB) has kicked off first quarter biotech earnings with a top- and bottom-line beat. However, the company surprised investors by announcing a …

This Analyst Takes Biogen (BIIB) Alzheimer’s Failure Personally

It’s a short and dramatic plunge for Biogen (BIIB) stock. Today, the biotech giant’s shares lost 29% of their value and reached levels …

Analyst Looks Beyond Biogen Inc (BIIB) Phase 2 Failure; Here’s Why the Drug Maker’s Second Alzheimer’s Asset Could Fare Differently Than BAN2401

Mizuho’s Salim Syed highlights 24% upside potential for BIIB shares, noting most investors were bracing themselves for this Phase II failure.

Biogen Inc (BIIB) Shares Slump as Spinraza US Sales Disappoint, But This Top Analyst Upbeat

Eric Schmidt views BIIB shares as undervalued based upon a stable MS franchise and Spinraza’s potential.

Let’s Hear It for Biogen Inc (BIIB) Drug Spinraza’s Blockbuster Potential, Raves Cowen Top Analyst

Coming off its successful launch of Spinraza, the first drug approved to treat children and adults with spinal muscular atrophy (SMA), Biogen Inc …

Biotech Insights: Alcobra Ltd (ADHD), Biogen Inc (BIIB), Juno Therapeutics Inc (JUNO)

Alcobra Ltd  Alcobra Ltd (NASDAQ:ADHD) lost half of its value today after announcing that the top-line results from MEASURE, the company’s second Phase …

Chardan Bullish on AveXis Inc (AVXS) Following Rival Spinraza Broad-Label Approval

Chardan analyst Gbola Amusa is placing his confidence behind AveXis Inc (NASDAQ:AVXS) even in light of competitors Biogen Inc (NASDAQ:BIIB) and Ionis Pharmaceuticals …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts